Clinical Trials Logo

Clinical Trial Summary

This phase II trial studies how well lenvatinib and pembrolizumab work in treating patients with anaplastic thyroid cancer that is stage IVB and has spread to nearby tissue or lymph nodes (locally advanced) and cannot be removed by surgery (unresectable), or stage IVC that has spread to other places in the body (metastatic). Lenvatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Given lenvatinib and pembrolizumab may work better than giving either one alone in treating stage IVB or C anaplastic thyroid cancer.


Clinical Trial Description

PRIMARY OBJECTIVE: I. Demonstrate the efficacy (overall survival [OS]) of lenvatinib plus pembrolizumab in treatment naive patients. SECONDARY OBJECTIVES: I. Determine the response rate and progression-free survival (PFS) in patients treated with lenvatinib plus pembrolizumab. II. Establish safety for concurrent administration of lenvatinib plus pembrolizumab. EXPLORATORY OBJECTIVE: I. Translational endpoints: cell-free deoxyribonucleic acid (DNA) changes and immune biomarkers will be studied. OUTLINE: Patients receive pembrolizumab intravenously (IV) over 30 minutes on day 1. Treatment repeats every 3 weeks for up to 35 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive lenvatinib orally (PO) daily on days 1-21. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up every 3 months for 2 years, every 6 months for 2 years, and then annually thereafter. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04171622
Study type Interventional
Source M.D. Anderson Cancer Center
Contact Maria E Cabanillas
Phone 713-792-2841
Email mcabani@mdanderson.org
Status Recruiting
Phase Phase 2
Start date November 4, 2021
Completion date August 31, 2025

See also
  Status Clinical Trial Phase
Active, not recruiting NCT04544111 - PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer Phase 2
Completed NCT01811212 - Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer Phase 2
Active, not recruiting NCT02393690 - Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer Phase 2
Active, not recruiting NCT03181100 - Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer Phase 2
Completed NCT02973997 - Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC) Phase 2
Recruiting NCT04759911 - Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer Phase 2
Active, not recruiting NCT03914300 - Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer Phase 2
Withdrawn NCT04731740 - Pembrolizumab and Lenvatinib/Chemotherapy for Poorly Differentiated/Anaplastic Thyroid Cancer Phase 2
Terminated NCT03630120 - Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer Phase 2
Active, not recruiting NCT02152995 - Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer Phase 2
Active, not recruiting NCT03449108 - LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas Phase 2